<![CDATA[What Needs to Happen Before Menin Inhibitors Move Into Frontline AML Combinations?]]>

RegulatoryrevumenibziftomenibPositive

AI Analysis

Summary

Menin inhibitors revumenib and ziftomenib may receive combination approvals in relapsed/refractory AML before frontline indications, according to expert commentary from Dr. Eunice Wang.

Outcome Details

Combination approvals expected for menin inhibitors in relapsed/refractory AML before frontline indications

Importance:5/10

Sentiment:

0.30

menin inhibitorAMLcombination therapyregulatory pathway

Related Companies

$SNDX $AYLA

Read the original article

Published by Cancer Network on September 10, 2026 3:30 PM

Read Original